Literature DB >> 51098

Production of antibody to individual polypeptides derived from purified hepatitis B surface antigen.

G R Dreesman, R Chairez, M Suarez, F B Hollinger, R J Courtney, J L Melnick.   

Abstract

Purified preparations of hepatitis B surface antigen (HBsAg) were solubilized with sodium dodecyl sulfate and urea under reducing conditions and subsequently fractionated by preparative sodium dodecyl sulfate-urea polyacrylamide gel electrophoresis (PAGE). Pools of the individual fractions eluted from the preparative PAGE were concentrated and purified further by analytical PAGE. Five purified polypeptides were isolated from HBsAg, types adw and ayw, with molecular weights of 19,000, 24,000, 27,000, 35,000, and 40,000. Each preparations was emulsified in Freund complete adjuvant and injected into guinea pigs. Antibody to each HBsAg type was measured by radioimmunoassay. The 19,000 molecular weight polypeptide derived from ayw particles and the 27,000 molecular weight subunit obtained from both types failed to elicit an antibody response. The other three polypeptides derived from the ayw particles elicited group-specific antibody responses. Similar group-specific reactivities were observed in the testing of anti-adw 35,000 and anti-adw 40,000 molecular weight polypeptide sera. However, guinea pigs immunized with the 19,000 and the 24,000 molecular weight polypeptides of the adw type produced antibody that reacted preferentially with adw particles. This indicates that either these subunits carry predominately d determinants or that, because of the low levels of material used for inoculation, no immune response or an undetectable one was elicited to the a or w components.

Entities:  

Mesh:

Substances:

Year:  1975        PMID: 51098      PMCID: PMC354697     

Source DB:  PubMed          Journal:  J Virol        ISSN: 0022-538X            Impact factor:   5.103


  26 in total

1.  Isolation and characterization of a large molecular-weight polypeptide of herpes simplex virus type 1.

Authors:  R J Courtney; M Benyesh-Melnick
Journal:  Virology       Date:  1974-12       Impact factor: 3.616

2.  Particles associated with Australia antigen in the sera of patients with leukaemia, Down's Syndrome and hepatitis.

Authors:  M E Bayer; B S Blumberg; B Werner
Journal:  Nature       Date:  1968-06-15       Impact factor: 49.962

3.  Characterization of hepatitis B antigen polypeptides.

Authors:  C R Howard; A J Zuckerman
Journal:  Intervirology       Date:  1974       Impact factor: 1.763

4.  Letter: Cross-reaction of human serum-proteins with HBsAg.

Authors:  A Goudeau; B Houwen; J Dankert
Journal:  Lancet       Date:  1974-11-30       Impact factor: 79.321

5.  Virus-like particles in serum of patients with Australia-antigen-associated hepatitis.

Authors:  D S Dane; C H Cameron; M Briggs
Journal:  Lancet       Date:  1970-04-04       Impact factor: 79.321

6.  Immune complexes in hepatitis.

Authors:  J D Almeida; A P Waterson
Journal:  Lancet       Date:  1969-11-08       Impact factor: 79.321

7.  Staphylococcal radioimmunoassay for hepatitis B antigen and antibody.

Authors:  K J Figenschau; J C Ulstrup
Journal:  Acta Pathol Microbiol Scand B Microbiol Immunol       Date:  1974-06

8.  [Hepatitis-associated antigen: purification and properties].

Authors:  W Gerlich; G May
Journal:  Zentralbl Bakteriol Orig A       Date:  1973-06

9.  New antigen-antibody system in Australia-antigen-positive hepatitis.

Authors:  J D Almeida; D Rubenstein; E J Stott
Journal:  Lancet       Date:  1971-12-04       Impact factor: 79.321

10.  Production of potent anti-Australia antigen sera of high specificity and sensitivity in goats.

Authors:  G R Dreesman; F B Hollinger; R M McCombs; J L Melnick
Journal:  Infect Immun       Date:  1972-02       Impact factor: 3.441

View more
  10 in total

1.  Cell-mediated immunity in guinea pigs to subunits derived from hepatitis B surface antigen.

Authors:  G A Cabral; R Chairez; F Marciano-Cabral; M Suarez; G R Dreesman; J L Melnick; F B Hollinger
Journal:  Infect Immun       Date:  1975-09       Impact factor: 3.441

2.  Polypeptide composition of HBsag.

Authors:  E Mineva; M Teoharova; S Ditzov; S Todorov
Journal:  Arch Virol       Date:  1977       Impact factor: 2.574

3.  Structural relationships between the surface antigens of ground squirrel hepatitis virus and human hepatitis B virus.

Authors:  W H Gerlich; M A Feitelson; P L Marion; W S Robinson
Journal:  J Virol       Date:  1980-12       Impact factor: 5.103

4.  Hepatitis B surface antigen polypeptides: artifactual bands in sodium dodecyl sulfate-polyacrylamide gel electrophoresis caused by aggregation.

Authors:  V U Koistinen
Journal:  J Virol       Date:  1980-07       Impact factor: 5.103

5.  Localization on the viral genome and nucleotide sequence of the gene coding for the two major polypeptides of the hepatitis B surface antigen (HBs Ag).

Authors:  P Charnay; E Mandart; A Hampe; F Fitoussi; P Tiollais; F Galibert
Journal:  Nucleic Acids Res       Date:  1979-09-25       Impact factor: 16.971

6.  Polypeptides of hepatitis B virus surface antigen produced by a hepatoma cell line.

Authors:  P L Marion; F H Salazar; J J Alexander; W S Robinson
Journal:  J Virol       Date:  1979-12       Impact factor: 5.103

Review 7.  The hepatitis B virus and its DNA polymerase: the prototype three-D virus.

Authors:  S Z Hirschman
Journal:  Mol Cell Biochem       Date:  1979-07-15       Impact factor: 3.396

Review 8.  Recent advances in the identification of hepatitis viruses.

Authors:  J L Dienstag; R H Purcell
Journal:  Postgrad Med J       Date:  1977-07       Impact factor: 2.401

9.  Mechanism of inactivation of hepatitis B surface antigen by N alpha-cocoyl-L-arginine ethyl ester.

Authors:  Y Sugimoto; S Toyoshima
Journal:  Antimicrob Agents Chemother       Date:  1981-07       Impact factor: 5.191

10.  Immunization of chimpanzees with hepatitis B virus-derived polypeptides.

Authors:  G R Dreesman; F B Hollinger; Y Sanchez; P Oefinger; J L Melnick
Journal:  Infect Immun       Date:  1981-04       Impact factor: 3.441

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.